Hyungoo Shin1, Jae Guk Kim2, Wonhee Kim3, Tae Ho Lim4, Bo-Hyoung Jang5, Youngsuk Cho6, Kyu-Sun Choi7, Chiwon Ahn8, Juncheol Lee9, Min Kyun Na10. 1. Department of Emergency Medicine, College of Medicine, Hanyang University Guri Hospital, Guri, Republic of Korea; Department of Emergency Medicine, Graduate School of Medicine, Hanyang University, Seoul, Republic of Korea. 2. Department of Emergency Medicine, College of Medicine, Hallym University, Chuncheon, Republic of Korea. 3. Department of Emergency Medicine, College of Medicine, Hallym University, Chuncheon, Republic of Korea; Department of Biomedical Engineering, Graduate School of Medicine, Hanyang University, Seoul, Republic of Korea. Electronic address: wonsee02@gmail.com. 4. Department of Emergency Medicine, College of Medicine, Hanyang University, Seoul, Republic of Korea. 5. Department of Preventive Medicine, College of Korean Medicine, Kyung Hee University, Seoul, Republic of Korea. 6. Department of Emergency Medicine, College of Medicine, Hallym University, Chuncheon, Republic of Korea; Department of Biomedical Engineering, Graduate School of Medicine, Hanyang University, Seoul, Republic of Korea. 7. Department of Neurosurgery, College of Medicine, Hanyang University, Seoul, Republic of Korea. 8. Department of Biomedical Engineering, Graduate School of Medicine, Hanyang University, Seoul, Republic of Korea; Department of Emergency Medicine, Armed Forces Yangju Hospital, Yangju, Republic of Korea. 9. Department of Emergency Medicine, Armed Forces Capital Hospital, Seongnam, Republic of Korea. 10. Department of Neurosurgery, Brain Tumour Centre, Severance Hospital, Yonsei University Health System, Seoul, Republic of Korea.
Abstract
AIM: This study aimed to seek evidence for the usefulness of the procalcitonin as a prognostic blood biomarker for outcomes in post-cardiac arrest patients. METHODS: We systematically searched MEDLINE, EMBASE, and the Cochrane Library (search date: 8 January, 2019). Studies on patients who experienced return of spontaneous circulation, who had out of hospital cardiac arrest and had their level of procalcitonin measured and outcomes assessed at and after hospital discharge, were included. We additionally performed subgroup analyses for confounding factors affecting patients' outcomes. To assess the risk of bias of each included study, the Quality in Prognosis Studies tool was used. RESULTS: A total of 1065 patients from 10 studies were finally included. Elevated procalcitonin level during hospital admission (at 0-24 h) was associated with in-hospital mortality (standardized mean difference (SMD) 0.64, 95% confidence interval (CI) 0.33-0.95, I2 = 26%). The elevation of procalcitonin level (at 0-48 h) was also associated with poor neurologic outcomes (at 0-24 h, SMD 0.61; 95% CI 0.44-0.79, I2 = 0%; at 24-48 h, SMD 0.58, 95% CI 0.35-0.82, I2 = 0%) as well as at 1-6 months (at 24-48 h, SMD 0.62; 95% CI 0.36-0.88, I2 = 0%). CONCLUSIONS: Overall, the findings suggested that an elevated procalcitonin level measured at 0-48 h of post-cardiac arrest syndrome was associated with poor outcomes.
AIM: This study aimed to seek evidence for the usefulness of the procalcitonin as a prognostic blood biomarker for outcomes in post-cardiac arrestpatients. METHODS: We systematically searched MEDLINE, EMBASE, and the Cochrane Library (search date: 8 January, 2019). Studies on patients who experienced return of spontaneous circulation, who had out of hospital cardiac arrest and had their level of procalcitonin measured and outcomes assessed at and after hospital discharge, were included. We additionally performed subgroup analyses for confounding factors affecting patients' outcomes. To assess the risk of bias of each included study, the Quality in Prognosis Studies tool was used. RESULTS: A total of 1065 patients from 10 studies were finally included. Elevated procalcitonin level during hospital admission (at 0-24 h) was associated with in-hospital mortality (standardized mean difference (SMD) 0.64, 95% confidence interval (CI) 0.33-0.95, I2 = 26%). The elevation of procalcitonin level (at 0-48 h) was also associated with poor neurologic outcomes (at 0-24 h, SMD 0.61; 95% CI 0.44-0.79, I2 = 0%; at 24-48 h, SMD 0.58, 95% CI 0.35-0.82, I2 = 0%) as well as at 1-6 months (at 24-48 h, SMD 0.62; 95% CI 0.36-0.88, I2 = 0%). CONCLUSIONS: Overall, the findings suggested that an elevated procalcitonin level measured at 0-48 h of post-cardiac arrest syndrome was associated with poor outcomes.
Authors: Ciler Zincircioglu; Tunzala Yavuz; Aykut Sarıtaş; Meltem Çakmak; Işıl Köse Güldoğan; Uğur Uzun; Nimet Şenoğlu Journal: Indian J Crit Care Med Date: 2020-05
Authors: Travis W Murphy; Scott A Cohen; K Leslie Avery; Meenakshi P Balakrishnan; Ramani Balu; Muhammad Abdul Baker Chowdhury; David B Crabb; Karl W Huesgen; Charles W Hwang; Carolina B Maciel; Sarah S Gul; Francis Han; Torben K Becker Journal: Resusc Plus Date: 2020-11-04